USP <788>

USP <788> is the compendial physical test for sub-visible particulate matter in injectable and infusion products — particles that are too small to be reliably caught by the visible inspection of USP <790> but large enough to pose a clinical safety concern (infusion-line embolism, vascular irritation, immunogenic response in biologics). The test counts particles at two diameters — ≥10 µm and ≥25 µm — and compares to compendial limits that depend on the fill volume (SVP for nominal volumes ≤100 mL, LVP for >100 mL). It does not differentiate by particle chemistry — glass, rubber, fibre, protein aggregate and air bubble all count if they hit the size threshold.

• Method 1 — Light Obscuration Particle Count Test. Single-particle light-obscuration sensor (HIAC or equivalent). Faster, lower per-test cost, automated; the default test for most parenteral release. Limitations: opaque or highly viscous products, products with refractive-index mismatch close to the suspending medium, and products with air bubbles that can spike counts.
• Method 2 — Microscopic Particle Count Test. Filter the sample through a 1.0 µm membrane, dry and visually count particles ≥10 µm and ≥25 µm under polarised-light microscopy at 100× magnification. Used when Method 1 cannot be applied (opaque, viscous, mismatched refractive index) or when Method 1 fails and a Method 2 confirmation is required.

The methods are not interchangeable. If a product specification calls for Method 1 but the product is incompatible, the method change is a validation activity and a filed change to the specification. Both methods must demonstrate suitability for the specific product matrix before use.

Limits are stricter under Method 2 because the microscopic counting captures particles that Method 1 may miss (e.g. flat fibres oriented along the laser beam). LVP limits are expressed per mL because container size varies (100 mL, 250 mL, 500 mL, 1 L, 3 L bags); SVP limits are per container because dose volume is small and clinically relevant. Specifications may be tighter than compendial limits — particularly for biologics where protein aggregates count and lot-to-lot consistency is critical.

1. Pool samples per <788>: typically 10 SVP containers ≤25 mL are pooled to make a single test volume; larger SVP containers are tested individually. LVPs are tested individually.
2. Degas — particle counters cannot distinguish air bubbles from real particles. Degas under vacuum or by gentle sonication; verify with a blank check.
3. Equilibrate to room temperature — temperature differentials cause Schlieren effects that perturb the laser signal.
4. Use particle-free water for any dilution or rinsing; verify the rinse blank meets a pre-defined low background.
5. Method 1 — five 5 mL runs per sample, ignore the first; report the average of the remaining four. Total volume tested per <788>.
6. Method 2 — entire pooled volume filtered onto a single membrane, stained as required, counted across at least 1/20th of the membrane area, with results scaled to the full membrane.

If both ≥10 µm and ≥25 µm averages are below the limits, the lot meets <788>. If either count exceeds the limit, the lot fails the compendial test and an OOS investigation is opened per USP <1010> and the company's OOS SOP. The investigation considers laboratory error first (degassing, contamination of glassware, blank check, environment), then product cause (container-closure, protein aggregation, fibre shedding from filters). Re-testing requires documented justification per the OOS procedure; a confirmed failure cannot be retested away.

Biologics typically apply tighter internal specifications and investigate trend signals (increasing 10 µm counts lot-over-lot) as out-of-trend (OOT) events even when the lot meets <788> — the chapter is a minimum, not a target.

Therapeutic protein products (mAbs, fusion proteins, peptides) can generate sub-visible particles from protein aggregation — silicone-oil droplets from the syringe, agitation during transit, freeze-thaw stress, glass-vial leachables. USP <787> is a low-volume light-obscuration adaptation specifically for therapeutic protein injections that tests less volume and avoids destroying scarce material. Sub-visible particle (SbVP) counting in the 2-10 µm range — below <788> reporting limits — is increasingly expected by FDA and EMA reviewers as part of biologic characterisation, using techniques like Micro-Flow Imaging (MFI), light obscuration with lower thresholds, and resonant mass measurement. Counts at 2-10 µm don't drive lot release but feed comparability assessment and immunogenicity risk.

Ophthalmic solutions are not parenteral by definition but the eye is similarly intolerant of particulate burden. USP <789> applies the same two methods with tighter limits (Method 1: 50 per mL at ≥10 µm and 5 per mL at ≥25 µm). Single-use ophthalmic preparations and multi-dose ophthalmic solutions both fall under <789>.

1. Counting air bubbles from inadequate degassing.
2. Pooling volume different from the procedure — under- or over-counting per the wrong divisor.
3. Method 1 used on opaque or highly-viscous product without justification.
4. Method 2 microscopic counting performed on only one field of the membrane with the result scaled — counting error explodes when sampling fraction is small.
5. Glassware contamination — class-A volumetric flasks not adequately rinsed with particle-free water.
6. Rinse blank not run on every test session; rising background unrecognised.
7. Repeat-tests run instead of an OOS investigation — testing into compliance.

• LIMS captures every <788> test session — operator, equipment serial, blank check, degassing record, pooled volume, raw counts, calculated average, registered spec, pass/fail flag.
• Method-suitability records held against the product master — Method 1 or Method 2, justification, validation report reference; the LIMS hard-blocks the wrong method against the wrong product.
• Blank-check thresholds enforced — a session with a rising rinse blank cannot proceed to the production-sample test until the background is restored.
• OOS workflow auto-fires on a failed result — no 'just rerun and see' option; the investigation must be opened, the laboratory error / product cause assessment documented, and the disposition recorded before any re-test is authorised.
• Trending dashboard: per-product running average ≥10 µm and ≥25 µm counts lot-over-lot, with Western Electric / Nelson OOT rules; a creeping particulate trend opens an OOT investigation before the lot fails the compendial limit.
• Biologics SbVP module: Micro-Flow Imaging or low-threshold light-obscuration results sit alongside <788> on the lot record, supporting comparability and immunogenicity assessment — without compromising the compendial release evidence.